Halozyme Therapeutics Approves Performance-Based Stock Grant for CEO

Details

Helen Torley, the Company's Chief Executive Officer. This one-time grant, with a target value of $10 million, is contingent upon the Company's stock price achieving specific thresholds over a four-year period and is also subject to Dr. Torley's continued employment with the Company. The grant aims to incentivize Dr. Torley to drive the Company's growth and profitability.

Items reported

About Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.